Formulary positioning and benefit design frequently determine utilization, as weak placement or reimbursement dynamics can ...

Integrated direct-to-patient models use AI-enabled eBenefits/eVerification plus real-time claims adjudication to surface ...

Supreme Court inaction leaves intact lower-court rulings rejecting takings and compelled-speech theories against “fair price” designations in Medicare price negotiation. Courts emphasized ...

Jeremy Richardson explains how direct-to-patient models increase drug pricing transparency and demonstrate value.

Makary’s tenure aligned FDA with MAHA priorities, including advocating placebo-controlled Covid-19 vaccine trials in ...

In today’s Pharma Pulse, FDA leadership changes with Makary’s resignation, Lilly shares new Zepbound and GLP-1 data, and new study data on prior authorization reform outlook. Welcome to Pharma Pulse, ...

Seventy-five executives across manufacturers and agencies backed a unified “system of work” to reduce multi-tool fragmentation across core commercial functions, reflecting a shift from tool ...

Will Shrank, MD, explains the main hurdles to specialty therapy access, and what will impact the market over the next few years. In the final part of Pharmaceutical Commerce’s conversation with Will ...

Pharma is moving from centralized patient hub services to a “hubless hub” model, using tech-enabled, distributed access tools to improve speed and outcomes. For decades, pharmaceutical companies have ...

Angelini Pharma is acquiring Catalyst Pharmaceuticals in a $4.1 billion transaction that expands its presence in the US rare ...